Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.9% – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s stock price dropped 3.9% on Monday . The stock traded as low as $1.40 and last traded at $1.49. Approximately 9,347,751 shares were traded during mid-day trading, an increase of 5,373% from the average daily volume of 170,796 shares. The stock had previously closed at $1.55.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, February 18th.

Citius Pharmaceuticals Price Performance

The stock’s 50 day moving average price is $2.12 and its 200-day moving average price is $5.30.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings results on Friday, February 14th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). As a group, research analysts anticipate that Citius Pharmaceuticals, Inc. will post -4.5 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Citius Pharmaceuticals by 103.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock valued at $33,000 after purchasing an additional 4,168 shares during the last quarter. Fisher Asset Management LLC bought a new position in Citius Pharmaceuticals during the fourth quarter valued at approximately $51,000. IFP Advisors Inc grew its holdings in Citius Pharmaceuticals by 21.2% during the 4th quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after buying an additional 7,083 shares in the last quarter. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals in the 3rd quarter worth approximately $47,000. Finally, Miller Investment Management LP raised its holdings in shares of Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares in the last quarter. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.